TUESDAY, Sept. 30, 2025 (HealthDay News) --...

TUESDAY, Sept. 30, 2025 (HealthDay News) --...

TUESDAY, Sept. 30, 2025 -- The U.S. Food and Drug Administration has approved Inluriyo (imlunestrant), an oral estrogen receptor antagonist, for the...

INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has...

INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has...

The FDA has approved Inluriyo, a first-in-class oral therapy for ESR1-mutated advanced breast cancer, marking a significant breakthrough. This new...

The FDA has approved Inluriyo, a first-in-class oral therapy for ESR1-mutated advanced breast cancer, marking a significant breakthrough. This new...

The Food and Drug Administration on Sept. 25 approved a new therapy for advanced breast cancer, based on data from a phase...

The Food and Drug Administration on Sept. 25 approved a new therapy for advanced breast cancer, based on data from a phase...

"FDA approved INLURIYO (imlunestrant) by Eli Lilly, on September 25, 2025" The pharmaceutical landscape for metastatic breast cancer treatment has...